Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/JCMA.0000000000000318 http://scihub22266oqcxt.onion/10.1097/JCMA.0000000000000318 32243270!7176266!32243270     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Chin+Med+Assoc 2020 ; 83 (6): 534-536 Nephropedia Template TP {{tp|p=32243270|t=2020. Potential therapeutic agents against COVID-19: What we know so far |pdf=|usr=}}{{32243270}} gab.com Text Potential therapeutic agents against COVID-19: What we know so far JO: J Chin Med Assoc http://www.kidney.de/pget.php?&tw=1&pmid=32243270 #FOAvip The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19. Twit Text FOAVip Potential therapeutic agents against COVID-19: What we know so far ????J Chin Med Assoc http://www.kidney.de/pget.php?&tw=1&pmid=32243270 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32243270 #FOAvip English Wikipedia <ref>{{Cite pmid|32243270}}</ref> Potential therapeutic agents against COVID-19: What we know so far #MMPMID32243270 Lu CC; Chen MY; Lee WS; Chang YL J Chin Med Assoc 2020[Jun]; 83 (6): 534-536 PMID32243270show ga The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19. |*Betacoronavirus[MESH] |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |COVID-19[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/*drug therapy[MESH] |Drug Combinations[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Interferon-alpha/therapeutic use[MESH] |Lopinavir/therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Ritonavir/therapeutic use[MESH]Potential therapeutic agents against COVID-19: What we know so far (epmc).pdf DeepDyve Pubget Overpricing